Alnylam Pharmaceuticals, Inc.

ALNY · Moat type: REGULIERUNG

MoatScore

6/10

Fair Value

71 USD

Margin of Safety

-338.9 %

Rating

BEOBACHTEN

GESCHÄFTSMODELL Alnylam Pharmaceuticals develops and commercializes RNA interference therapeutics (RNAi) that selectively "silence" disease-causing proteins at the genetic level, and generates revenue through product sales of approved medications as well as licensing and milestone payments from partners.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.